[go: up one dir, main page]

DK0810870T3 - Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf - Google Patents

Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf

Info

Publication number
DK0810870T3
DK0810870T3 DK95914792T DK95914792T DK0810870T3 DK 0810870 T3 DK0810870 T3 DK 0810870T3 DK 95914792 T DK95914792 T DK 95914792T DK 95914792 T DK95914792 T DK 95914792T DK 0810870 T3 DK0810870 T3 DK 0810870T3
Authority
DK
Denmark
Prior art keywords
tumor rejection
rejection antigen
antigen precursor
derived tumor
complexes
Prior art date
Application number
DK95914792T
Other languages
Danish (da)
English (en)
Inventor
Cornelis J M Melief
M W Visseren
W M Kast
Der Bruggen Pierre Van
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Univ Leiden filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK0810870T3 publication Critical patent/DK0810870T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK95914792T 1994-03-24 1995-03-21 Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf DK0810870T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,188 US5554724A (en) 1994-03-24 1994-03-24 Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
PCT/US1995/003535 WO1995025530A1 (fr) 1994-03-24 1995-03-21 Isolation et utilisations de peptides derives de mage-2, un precurseur d'antigene de rejet tumoral

Publications (1)

Publication Number Publication Date
DK0810870T3 true DK0810870T3 (da) 2001-07-23

Family

ID=22810016

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95914792T DK0810870T3 (da) 1994-03-24 1995-03-21 Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf

Country Status (17)

Country Link
US (3) US5554724A (fr)
EP (1) EP0810870B1 (fr)
JP (1) JP3360137B2 (fr)
CN (1) CN1149257A (fr)
AT (1) ATE201214T1 (fr)
AU (1) AU682597B2 (fr)
CA (1) CA2186006A1 (fr)
DE (1) DE69520959T2 (fr)
DK (1) DK0810870T3 (fr)
ES (1) ES2158943T3 (fr)
FI (1) FI963780A7 (fr)
GR (1) GR3036320T3 (fr)
NO (1) NO963918L (fr)
NZ (2) NZ329695A (fr)
PT (1) PT810870E (fr)
WO (1) WO1995025530A1 (fr)
ZA (1) ZA952375B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
AU740222C (en) * 1996-03-20 2002-10-10 Genzyme Corporation A method for identifying cytotoxic T-cell epitopes
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6326200B1 (en) 1997-06-23 2001-12-04 Ludwig Institute For Cancer Research Isolated nona-and decapeptides which bind to HLA molecules, and the use thereof
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
EP1103561B1 (fr) * 1998-07-28 2006-04-19 Green Peptide Co., Ltd. Peptide d'antigene de tumeur limitant hla-a2 provenant de sart-1
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
WO2001030382A1 (fr) 1999-10-22 2001-05-03 Aventis Pasteur Limited Procede visant a provoquer et/ou stimuler une reponse immunitaire aux antigenes tumoraux
EP1282702B1 (fr) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
WO2005035773A2 (fr) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Vecteur cea/b7 modifie
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
WO2004037284A1 (fr) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Vaccins anticancereux et cytokines a haute dose utilisees comme adjuvants
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
WO2006113540A2 (fr) 2005-04-14 2006-10-26 Duke University Utilisation d'un agent qui restaure l'irrigation et l'oxygenation des tissus
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
CA2774636C (fr) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants diriges contre le vih-1 et utilisation associee
EP2683350A4 (fr) 2011-03-07 2015-08-05 Creative Nail Design Inc Compositions de revêtements cosmétiques pour ongles durcissables par uv et procédés associés
EP2825572B1 (fr) 2012-03-15 2022-07-27 ExxonMobil Chemical Patents Inc. Adaptation par l'oxygène de polyéthylène
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ATE342730T1 (de) * 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
WO1994020127A1 (fr) * 1993-03-05 1994-09-15 Cytel Corporation Peptides se liant a hla-a2.1 et leurs utilisations
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
CN1149257A (zh) 1997-05-07
ATE201214T1 (de) 2001-06-15
AU682597B2 (en) 1997-10-09
FI963780L (fi) 1996-09-23
DE69520959D1 (de) 2001-06-21
FI963780A0 (fi) 1996-09-23
CA2186006A1 (fr) 1995-09-28
NZ283561A (en) 1998-04-27
NO963918D0 (no) 1996-09-19
NO963918L (no) 1996-11-20
JPH10502329A (ja) 1998-03-03
DE69520959T2 (de) 2002-03-28
EP0810870A1 (fr) 1997-12-10
AU2189395A (en) 1995-10-09
FI963780A7 (fi) 1996-09-23
US5554724A (en) 1996-09-10
ZA952375B (en) 1995-12-15
JP3360137B2 (ja) 2002-12-24
ES2158943T3 (es) 2001-09-16
EP0810870A4 (fr) 1998-11-25
NZ329695A (en) 2000-05-26
EP0810870B1 (fr) 2001-05-16
PT810870E (pt) 2001-09-28
WO1995025530A1 (fr) 1995-09-28
US6147187A (en) 2000-11-14
GR3036320T3 (en) 2001-11-30
US6063900A (en) 2000-05-16

Similar Documents

Publication Publication Date Title
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
den Haan et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen
ATE183195T1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
CA2186004A1 (fr) Peptides isoles derives de precurseurs de l'antigene mage de rejet des tumeurs se complexant avec les molecules d'hla-a2
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
ATE447585T1 (de) Antigener komplex, der ein immunstimulierendes peptid enthält, cd4 und chemokinrezeptor-domäne zur behandlung von hiv und immunerkrankungen
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
RU2009130954A (ru) Применение белков теплового шока для улучшения терапевтического эффекта невакционного лечебного воздействия
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
EA200702202A1 (ru) Идентификация представленных hla-a2 т-клеточных эпитопов, полученных из раково-эмбрионального антиген-незрелого рецепторного белка ламинила, и их применение
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ATE509025T1 (de) ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
GB9826143D0 (en) Tumour rejection antigens
ATE336579T1 (de) Isolierte mhc-klasse ii-bindende peptide, und deren verwendung
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier
Nguyen et al. Recognition of breast cancer‐associated peptides by tumor‐reactive, HLA‐class I restricted allogeneic cytotoxic T lymphocytes
PT996636E (pt) Antigenio ha-1
ATE207757T1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
RU98104739A (ru) Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
Myeloma-Reactive et al. Targeting Positive Regulatory Domain
ITMI20042227A1 (it) Peptide in grado di rompere il complesso m-p53-p63, m-p53-p73 e m-p53-relative proteine isoformi formatosi nelle cellule tumorali e relativi impieghi in campo farmacologico
EP1377304A4 (fr) Nouvelle isoforme de la trp2 contenant des epitopes cytotoxiques de lymphocytes t a restriction de hla-a2